Company intelligence
SJLife Sciences
part of The SJGroup
About SJLife Sciences
SJLife Sciences are a Global Talent Partner that exclusively serves the Pharmaceutical, Biotechnology, Medical Device, and CRO sectors. Our Mission is to provide a focused, quality-driven consultative offering that combines an exceptional market understanding of the Life Science industry with a dedication and passion to go above and beyond for our clients and candidates. We want to do more than just recruit the right people for the right role. We want to build partnerships that change people's lives. We recognize the expanding and growing need for talent within the life sciences industry, which is why we have consultants dedicated to placing candidates with the right skills and experience across our European and US markets. Combined with our expertise and deep knowledge of the life sciences industry, we can become your lifelong partner in an exciting career. Whether you’re potentially looking for a new opportunity or looking to attract talent to your team, we’d love to hear from you.
Verified activity
Signals from SJLife Sciences
11 published signals
Capital & Finance
SJLife Sciences reported that the Phase 3 Harbor trial of del-desiran for Novartis' $12B Avidity acquisition of Avidity Biosciences, Inc. missed its primary endpoint in myotonic dystrophy type 1.
Reported by Grant Smillie
Legal & Regulatory
SJLife Sciences noted that Ultragenyx missed its primary and key secondary endpoints in the Ph 3 Aspire study of apazunersen in Angelman syndrome.
Reported by Grant Smillie
Legal & Regulatory
SJLife Sciences noted that Takeda secured approval in Japan for ORZEYFUL, targeting narcolepsy type 1.
Reported by Grant Smillie
Legal & Regulatory
SJLife Sciences noted that Roche received FDA clearance for its Elecsys pTau217 blood test to support Alzheimer’s disease assessment.
Reported by Grant Smillie
Legal & Regulatory
SJLife Sciences noted that MIRA Pharmaceuticals reported positive tox data for MIRA-55, supporting IND enabling studies in inflammatory pain.
Reported by Grant Smillie
Legal & Regulatory
SJLife Sciences noted that Axsome Therapeutics, Inc. dosed the first patient in their Ph 3 of AXS-05 for smoking cessation.
Reported by Grant Smillie
Legal & Regulatory
SJLife Sciences noted that Alkermes published positive Ph 2 data for alixorexton targetting narcolepsy type 1, supporting their ongoing Ph 3 programme.
Reported by Grant Smillie
People
SJLife Sciences appointed Grant Smillie as the Principal Investigators for three roles in Michigan, Dallas, and Phoenix.
Reported by Grant Smillie
People
SJLife Sciences appointed Grant Smillie as the Director of the Drug Substance Lead role with a 100% time contract.
Reported by Grant Smillie
People
SJLife Sciences appointed Grant Smillie as the Director of the CMC Project Manager role with a 100% time contract.
Reported by Grant Smillie
People
SJLife Sciences appointed Grant Smillie as the Director of the Access Lead role.
Reported by Grant Smillie